There is growing recognition and subsequent real concern about the number of young people who are now reporting diminished cognitive functioning after having been infected with COVID 19. These reports are from those with severe to asymptomatic experiences of acute infection and the chronic symptoms have surfaced sometimes months post recovery. Our view is that the global neuroinflammatory and thrombotic effects are key drivers for long COVID neurological symptoms and that 1070nm transcranial photobiomodulation (TPBM) can offer a method for symptom mitigation.
Quietmind and Neuronic Devices Ltd. (neuronic.online) are collaborating with our colleagues at Durham Univ. and the Univ. of Texas-Arlington to study the variable impact of the Neuradiant 1070 4Q device on infectivity, virulence and post infection neuropsychological and neurophysiological symptoms.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.